A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. - VERITAC-2 - Arvinas Estrogen Receptor, Inc.See more
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment - PfizerSee more
Lung cancer
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer - GlaxoSmithKlineSee more
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
Cardiovascular disease
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease - TRIUMPH-3 - Eli Lilly and CompanySee more
MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD - Merck Sharp & Dohme LLCSee more
Diabetes
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) - Eli Lilly and CompanySee more
Esophageal cancer
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. - FORTITUDE-102 - AmgenSee more
Gastric cancer
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. - FORTITUDE-102 - AmgenSee more
Gastroesophageal cancer
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. - FORTITUDE-102 - AmgenSee more
Head and neck cancer
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma - JADE - GlaxoSmithKlineSee more
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
Liposarcoma
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
Lupus
A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy - AMETHYST - BiogenSee more
Obesity
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease - TRIUMPH-3 - Eli Lilly and CompanySee more
Prostate cancer
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more
Rare diseases
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome - POETYK SjS-1 - Bristol-Myers SquibbSee more
Skin cancer
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) - MK-3475A-F11 - Merck Sharp & Dohme LLCSee more
Solid tumors
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more